MiMedx To Host Virtual 2020 Annual Meeting of Shareholders on Friday, November 20
November 13 2020 - 8:00AM
MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an
industry leader in advanced wound care and a therapeutic biologics
company, today provided additional information about its upcoming
virtual 2020 Annual Meeting of Shareholders (“Annual Meeting”).
Timothy R. Wright, Chief Executive Officer, is scheduled to present
an overview of the Company, and Rohit Kashyap, Ph.D., Executive
Vice President and Chief Commercial Officer, and Robert B. Stein,
M.D., Ph.D., Executive Vice President, Research and Development,
are scheduled to present an overview of the Company’s commercial
and R&D initiatives. Additional members of senior management
also plan to be available for a question and answer session from
shareholders as of the record date of 5:00 p.m. Eastern Time on
October 7, 2020. Guests may join the virtual 2020 Annual Meeting,
including the shareholder question and answer session, in a
listen-only mode without a control number.
The meeting is scheduled to be held on Friday,
November 20, 2020 at 10:00 a.m. Eastern Time and will be conducted
in a virtual format only in light of public health concerns
regarding the coronavirus (COVID-19) outbreak.
To participate in the virtual Annual Meeting,
shareholders must
visit www.virtualshareholdermeeting.com/MDXG2020 on Friday,
November 20, 2020 and enter the 16-digit control number found on
their proxy materials or voting instruction form. Please log in at
least 15 minutes before the Annual Meeting begins to ensure ample
time to complete the check-in procedures and test your computer
audio system. Presentation materials will be posted on the Webcasts
& Presentations section of the Company’s website immediately
prior to the start of the meeting.
The Company has filed its definitive proxy
statement with the U.S. Securities and Exchange Commission (“SEC”)
and has mailed it with an accompanying proxy card for the virtual
2020 Annual Meeting to its shareholders. A free copy of the Proxy
Statement and other relevant documents that the Company files with
the SEC may be obtained through the SEC’s website at www.sec.gov or
on the Company’s website at www.mimedx.com.
About
MiMedxMiMedx® is an industry leader in advanced
wound care and a therapeutic biologics company developing and
distributing human placental tissue allografts with
patent-protected processes for multiple sectors of healthcare. The
Company processes the human placental tissue utilizing its
proprietary PURION® process methodology, among other processes, to
produce allografts by employing aseptic processing techniques in
addition to terminal sterilization. MiMedx has supplied more than
two million allografts, through both direct and consignment
shipments. For additional information, please visit
www.mimedx.com.
ContactHilary DixonInvestor
Relations & Corporate
Communications770.651.9066investorrelations@mimedx.com
MiMedx (NASDAQ:MDXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
MiMedx (NASDAQ:MDXG)
Historical Stock Chart
From Apr 2023 to Apr 2024